Literature DB >> 22302226

Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?

Richard L Theriault1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22302226      PMCID： PMC3286161          DOI： 10.1634/theoncologist.2011-0371

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  28 in total

1.  American College of Physicians Ethics Manual: sixth edition.

Authors:  Lois Snyder
Journal:  Ann Intern Med       Date:  2012-01-03       Impact factor: 25.391

2.  An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.

Authors:  Wen Chen; Zefei Jiang; Zhimin Shao; Qiang Sun; Kunwei Shen
Journal:  Value Health       Date:  2009 Nov-Dec       Impact factor: 5.725

3.  Delivering affordable cancer care in high-income countries.

Authors:  Richard Sullivan; Jeffrey Peppercorn; Karol Sikora; John Zalcberg; Neal J Meropol; Eitan Amir; David Khayat; Peter Boyle; Philippe Autier; Ian F Tannock; Tito Fojo; Jim Siderov; Steve Williamson; Silvia Camporesi; J Gordon McVie; Arnie D Purushotham; Peter Naredi; Alexander Eggermont; Murray F Brennan; Michael L Steinberg; Mark De Ridder; Susan A McCloskey; Dirk Verellen; Terence Roberts; Guy Storme; Rodney J Hicks; Peter J Ell; Bradford R Hirsch; David P Carbone; Kevin A Schulman; Paul Catchpole; David Taylor; Jan Geissler; Nancy G Brinker; David Meltzer; David Kerr; Matti Aapro
Journal:  Lancet Oncol       Date:  2011-09       Impact factor: 41.316

4.  The climbing costs of cancer care.

Authors:  Norra Macready
Journal:  J Natl Cancer Inst       Date:  2011-09-20       Impact factor: 13.506

5.  Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States.

Authors:  Mark D Danese; Deepa Lalla; Melissa Brammer; Quan Doan; Kevin Knopf
Journal:  Cancer       Date:  2010-08-23       Impact factor: 6.860

6.  Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.

Authors:  Timo T Purmonen; Emma Pänkäläinen; Juha H O Turunen; Christian Asseburg; Janne A Martikainen
Journal:  Acta Oncol       Date:  2011-02-08       Impact factor: 4.089

7.  Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.

Authors:  Peter S Hall; Claire Hulme; Christopher McCabe; Yemi Oluboyede; Jeff Round; David A Cameron
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.981

8.  Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application.

Authors:  Jennifer M Duff; Helen Leather; Edmund O Walden; Kourtney D LaPlant; Thomas J George
Journal:  J Natl Cancer Inst       Date:  2010-04-21       Impact factor: 13.506

9.  The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.

Authors:  Chris Skedgel; Daniel Rayson; Tallal Younis
Journal:  Value Health       Date:  2009 Jul-Aug       Impact factor: 5.725

10.  Societal costs and benefits of treatment with trastuzumab in patients with early HER2neu-overexpressing breast cancer in Singapore.

Authors:  Gilberto de Lima Lopes
Journal:  BMC Cancer       Date:  2011-05-18       Impact factor: 4.430
View more
  4 in total

1.  Should be NICE have a Spanish NICE?

Authors:  J Feliu; E Espinosa
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

Review 2.  Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review.

Authors:  Janne C Mewes; Lotte M G Steuten; Maarten J Ijzerman; Wim H van Harten
Journal:  Oncologist       Date:  2012-09-14

3.  "Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance?

Authors:  Leonard M Fleck
Journal:  J Pers Med       Date:  2013-07-16

4.  Treatment of breast cancer patients from a public healthcare system in a private center: costs of care for a pilot public-private partnership in oncology.

Authors:  Rafael Aliosha Kaliks; Lucíola de Barros Pontes; Cinthia Leite Frizzera Borges Bognar; Kelly Cristine Carvalho Santos; Sílvio Eduardo Bromberg; Paulo Gustavo Tenório do Amaral; Theodora Karnakis; Michael Chen; Cláudia Toledo de Andrade; Joacira Dantas; Daísa de Mesquita Escobosa; Auro Del Giglio
Journal:  Einstein (Sao Paulo)       Date:  2013 Apr-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.